Dr Patrick Mclaughlin, DMD | |
26 Quail Hollow Dr, Milton, VT 05468-3578 | |
(802) 338-8628 | |
Not Available |
Full Name | Dr Patrick Mclaughlin |
---|---|
Gender | Male |
Speciality | Dentist - General Practice |
Location | 26 Quail Hollow Dr, Milton, Vermont |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1487271094 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1223G0001X | Dentist - General Practice | 016.0133951 (Vermont) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Patrick Mclaughlin, DMD 26 Quail Hollow Dr, Milton, VT 05468-3578 Ph: (802) 338-8628 | Dr Patrick Mclaughlin, DMD 26 Quail Hollow Dr, Milton, VT 05468-3578 Ph: (802) 338-8628 |
News Archive
The information critical to a nationwide priority of reducing health care disparities among minorities is incomplete and inaccurate, according to a new Rutgers study.
The Epilepsy Research Foundation (ERF), a unique joint venture of non-profit epilepsy organizations, and the Milken Family Foundation, a private philanthropic foundation, today announced two new grants recognizing promising epilepsy research in clinical development, totaling $225,000 in funding. The grant awards were announced by the Epilepsy Therapy Project and the Epilepsy Foundation, as well as the Milken Family Foundation, during the 7th Judith Hoyer Lecture in Epilepsy at the annual meeting of the American Epilepsy Society in Boston, MA.
MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in film pharmaceutical products, in collaboration with APR Applied Pharma Research s.a. of Switzerland and Labtec GmbH of Germany, today announced that its partner, Strativa Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for Zuplenz® oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.
Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.
› Verified 8 days ago
Dr. Cedric Charles Pecor, D.D.S. Dentist Medicare: Medicare Enrolled Practice Location: 157 River St, Milton, VT 05468 Phone: 802-893-4734 | |
Dr. James Simollardes, D.D.S. Dentist Medicare: Medicare Enrolled Practice Location: 33 School St, Milton, VT 05468 Phone: 802-893-2552 | |
Dr. Bethany K Fitzgerald, DDS Dentist Medicare: Medicare Enrolled Practice Location: 157 River St, Milton, VT 05468 Phone: 802-893-4734 | |
Dr. Edward Rowe Klingebiel, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 157 River St, Milton, VT 05468 Phone: 802-893-4734 |